Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

BLRX stock hub

BioLineRx Ltd. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BLRXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

14.4M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

BLRX

In the news

Latest news · BLRX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-11

P25 -105.6P50 -46.5P75 -3.1

ROIC-20.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BLRX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

196

Groups with data

Currency

USD

Showing 196 of 196 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001498403
Company name	BioLineRx Ltd.
Country	Israel
Country code	US
Cusip	09071M304
Employees	24
Employees Change	-4%
Employees Change Percent	-14.29
Enterprise value	$8.3M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2011-07-25
Isin	US09071M3043
Last refreshed	2026-05-10
Market cap	$14.4M
Market cap category	Nano-Cap
Price	$3.07
Price currency	USD
Rev Per Employee	49,166.67x
Sector	Healthcare
Sic	2834
Symbol	BLRX
Website	https://www.biolinerx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-8.15%
EV/Sales	7.01x
FCF yield	-56.21%
P/B ratio	0.62x
P/S ratio	12.21x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	80.51%
Gross Profit	$950,000
Gross Profit Growth	-95.17%
Gross Profit Growth Q	-97.28%
Net Income	$-1.2M
Net Income Growth Quarters	2%
Net Income Growth Years	2%
Pretax Margin	-171.69%
Profit Margin	-99.58%
Profit Per Employee	$-48,958
ROA	-16.11
Roa5y	-24.97
ROCE	-35.74
ROE	-11.01
Roe5y	-74.27
ROIC	-20.74

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-40.44%
Cagr1y	-2.85%
Cagr3y	-59.89%
Cagr5y	-53.99%
EPS Growth Years	0
Revenue Growth	-95.92x
Revenue Growth Q	-98.35x
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.03
Assets	$40.9M
Cash	$20.9M
Current Assets	$23.7M
Current Liabilities	$12.1M
Debt	$10.2M
Debt Equity	$0.43
Equity	$23.3M
Interest Coverage	-8.22
Liabilities	$17.6M
Long Term Assets	$17.2M
Long Term Liabilities	$5.4M
Net Cash	$10.7M
Net Cash By Market Cap	$74.44
Net Cash Growth	137.2%
Net Debt Equity	$-0.46
Tangible Book Value	$1.8M
Tangible Book Value Per Share	$0
WACC	8.42

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.95
Inventory Turnover	0.09
Net Working Capital	$-4.6M
Quick ratio	1.76
Working Capital	$11.6M
Working Capital Turnover	$0.1

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-105.76%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-99.44%
1Y total return	-2.85%
200-day SMA	3.22
3Y total return	-93.55%
50-day SMA	2.56
50-day SMA vs 200-day SMA	50under200
5Y total return	-97.94%
All Time High	4,122
All Time High Change	-99.93%
All Time High Date	2012-01-24
All Time Low	2.15
All Time Low Change	42.79%
All Time Low Date	2026-04-01
ATR	0.22
Beta	0.59
Ch YTD	10.83
High	3.18
High52	7.77
High52 Date	2025-05-30
High52ch	-60.49%
Low	3
Low52	2.15
Low52 Date	2026-04-01
Low52ch	42.79%
Ma50ch	19.97%
Price vs 200-day SMA	-4.69%
RSI	61.48
RSI Monthly	32.91
RSI Weekly	50.41
Sharpe ratio	0.29x
Sortino ratio	0.58
Total Return	-105.76%
Tr YTD	10.83
Tr1m	35.24%
Tr1w	7.22%
Tr3m	3.02%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-1.04
Earnings Revenue Estimate	343,000x
Earnings Revenue Estimate Growth	34.51x
Operating Income	$-10.3M
Operating margin	-871.8
Price target	$19
Price Target Change	$519

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2,498,163,190%
Float Percent	95.69%
Net Borrowing	-5,010,000
Shares Insiders	0.39%
Shares Institutions	3.97%
Shares Out	2,610,814,390
Shares Qo Q	2.12%
Shares Yo Y	105.76%
Short Ratio	8.9
Short Shares	3.56

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-8.5M
Average Volume	27,148.45x
Bv Per Share	0.01
CAPEX	$-25,000
Ch10y	-99.44
Ch1m	35.24
Ch1w	7.23
Ch1y	-2.85
Ch3m	3.02
Ch3y	-93.55
Ch5y	-97.94
Ch6m	-6.12
Change	-0.97%
Change From Open	-2.23
Close	3.1
Days Gap	1.29
Depreciation Amortization	227,000
Dollar Volume	39,160.3
Earnings Date	2026-05-26
Earnings Time	bmo
EBIT	$-10.3M
EBITDA	$-10.1M
EPS	$-0
F Score	3
FCF	$-8.1M
FCF EV Yield	-97.86x
FCF Per Share	$-0
Financing CF	8,884,000
Fiscal Year End	December
Founded	2,003
Investing CF	-8,545,000
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-03-23
Last Report Date	2025-12-31
Last Split Date	2025-01-30
Last Split Type	Reverse
Last10k Filing Date	2026-03-23
Ma150	3.02
Ma150ch	1.72%
Ma20	2.63
Ma20ch	16.91%
Net CF	-7,186,000
Next Earnings Date	2026-05-26
Open	3.14
Optionable	Yes
Position In Range	39.55
Post Close	3.07
Postmarket Change Percent	-2.28
Postmarket Price	$3
Ppne	856,000
Price Date	2026-05-08
Ptbv Ratio	7.88
Relative Volume	0.47x
Revenue	1,180,000x
SBC By Revenue	33.56x
Share Based Comp	396,000
Tr6m	-6.12%
Volume	12,755.8
Z Score	-13.64

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does BLRX pay a dividend?

Capital-return profile for this ticker.

Performance

BLRX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BLRX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+4.0%

Float: +95.7% of shares outstanding

Insider ownership

+0.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

BLRX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

61.5

Neutral momentum band

Price vs 200-day MA

-4.7%

50/200-day relationship not available

Beta (5Y)

0.59

Less volatile than the market

Sharpe ratio

0.29

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BLRX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current BLRX stock rating?

BioLineRx Ltd. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BLRX analysis?

The full report lives at /stocks/BLRX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for BLRX?

The latest report frames BLRX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the BLRX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.